| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Time trends in primary HIV-1 drug resistance among recently infected persons.
|
JAMA
|
2002
|
4.02
|
|
2
|
Treatment benefit on cerebrospinal fluid HIV-1 levels in the setting of systemic virological suppression and failure.
|
J Infect Dis
|
2006
|
2.36
|
|
3
|
Prospective antiretroviral treatment of asymptomatic, HIV-1 infected controllers.
|
PLoS Pathog
|
2013
|
2.06
|
|
4
|
Differential persistence of transmitted HIV-1 drug resistance mutation classes.
|
J Infect Dis
|
2011
|
1.90
|
|
5
|
Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection.
|
J Infect Dis
|
2005
|
1.76
|
|
6
|
Interruption of enfuvirtide in HIV-1 infected adults with incomplete viral suppression on an enfuvirtide-based regimen.
|
J Infect Dis
|
2006
|
1.62
|
|
7
|
Central nervous system immune activation characterizes primary human immunodeficiency virus 1 infection even in participants with minimal cerebrospinal fluid viral burden.
|
J Infect Dis
|
2011
|
1.59
|
|
8
|
Transmitted drug resistance in persons with acute/early HIV-1 in San Francisco, 2002-2009.
|
PLoS One
|
2010
|
1.39
|
|
9
|
Assessment of population-based HIV RNA levels in a rural east African setting using a fingerprick-based blood collection method.
|
Clin Infect Dis
|
2012
|
1.26
|
|
10
|
Rate of viral evolution and risk of losing future drug options in heavily pretreated, HIV-infected patients who continue to receive a stable, partially suppressive treatment regimen.
|
Clin Infect Dis
|
2006
|
1.26
|
|
11
|
Expression profile of host restriction factors in HIV-1 elite controllers.
|
Retrovirology
|
2013
|
1.24
|
|
12
|
The independent effect of drug resistance on T cell activation in HIV infection.
|
AIDS
|
2006
|
1.22
|
|
13
|
Dual pressure from antiretroviral therapy and cell-mediated immune response on the human immunodeficiency virus type 1 protease gene.
|
J Virol
|
2003
|
1.19
|
|
14
|
Drug resistance and plasma viral RNA level after ineffective use of oral pre-exposure prophylaxis in women.
|
AIDS
|
2015
|
1.10
|
|
15
|
Persistence of drug-resistant HIV-1 after a structured treatment interruption and its impact on treatment response.
|
AIDS
|
2003
|
1.10
|
|
16
|
Early virologic failure and the development of antiretroviral drug resistance mutations in HIV-infected Ugandan children.
|
J Acquir Immune Defic Syndr
|
2011
|
1.04
|
|
17
|
High-risk sexual behavior in adults with genotypically proven antiretroviral-resistant HIV infection.
|
J Acquir Immune Defic Syndr
|
2005
|
1.03
|
|
18
|
Isolated lopinavir resistance after virological rebound of a ritonavir/lopinavir-based regimen.
|
AIDS
|
2004
|
0.97
|
|
19
|
Changes in population HIV RNA levels in Mbarara, Uganda, during scale-up of HIV antiretroviral therapy access.
|
J Acquir Immune Defic Syndr
|
2014
|
0.92
|
|
20
|
Comparative frequencies of HIV low-level viremia between real-time viral load assays at clinically relevant thresholds.
|
J Clin Virol
|
2011
|
0.90
|
|
21
|
Novel application of Locked Nucleic Acid chemistry for a Taqman assay for measuring diverse human immunodeficiency virus type 1 subtypes.
|
J Virol Methods
|
2010
|
0.89
|
|
22
|
Effects of alpha interferon treatment on intrinsic anti-HIV-1 immunity in vivo.
|
J Virol
|
2013
|
0.89
|
|
23
|
The cerebrospinal fluid proteome in HIV infection: change associated with disease severity.
|
Clin Proteomics
|
2012
|
0.88
|
|
24
|
Modification of the Abbott RealTime assay for detection of HIV-1 plasma RNA viral loads less than one copy per milliliter.
|
J Virol Methods
|
2011
|
0.88
|
|
25
|
Cerebrospinal fluid in HIV-1 systemic viral controllers: absence of HIV-1 RNA and intrathecal inflammation.
|
AIDS
|
2010
|
0.86
|
|
26
|
Enfuvirtide cerebrospinal fluid (CSF) pharmacokinetics and potential use in defining CSF HIV-1 origin.
|
Antivir Ther
|
2008
|
0.85
|
|
27
|
Genotypic resistance and immunologic outcomes among HIV-1-infected women with viral failure.
|
J Acquir Immune Defic Syndr
|
2006
|
0.85
|
|
28
|
Increased adolescent HIV testing with a hybrid mobile strategy in Uganda and Kenya.
|
AIDS
|
2016
|
0.84
|
|
29
|
Unexpected low-level viremia among HIV-infected Ugandan adults with untreated active tuberculosis.
|
J Acquir Immune Defic Syndr
|
2008
|
0.83
|
|
30
|
Select host restriction factors are associated with HIV persistence during antiretroviral therapy.
|
AIDS
|
2015
|
0.81
|
|
31
|
Targeting of conserved gag-epitopes in early HIV infection is associated with lower plasma viral load and slower CD4(+) T cell depletion.
|
AIDS Res Hum Retroviruses
|
2013
|
0.80
|
|
32
|
Is there an association between HIV-1 genital shedding and cervical intraepithelial neoplasia 2/3 among women on antiretroviral therapy?
|
J Low Genit Tract Dis
|
2013
|
0.78
|
|
33
|
Brief Report: Recent Infection, Sexually Transmitted Infections, and Transmission Clusters Frequently Observed Among Persons Newly Diagnosed With HIV in San Francisco.
|
J Acquir Immune Defic Syndr
|
2015
|
0.77
|
|
34
|
Attrition and Opportunities Along the HIV Care Continuum: Findings From a Population-Based Sample, North West Province, South Africa.
|
J Acquir Immune Defic Syndr
|
2016
|
0.76
|
|
35
|
Dehydroepiandrosterone (DHEA) effects on HIV replication and host immunity: a randomized placebo-controlled study.
|
AIDS Res Hum Retroviruses
|
2007
|
0.76
|
|
36
|
Association of cervical biopsy with HIV type 1 genital shedding among women on highly active antiretroviral therapy.
|
AIDS Res Hum Retroviruses
|
2013
|
0.75
|